|
Market Closed -
NSE India S.E.
16:11:06 14/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 1,930.00 INR | -0.10% |
|
-1.08% | +12.23% |
| 08-05 | CRISIL Keeps AAA Rating on Sun Pharmaceutical's Bank Facilities | MT |
| 07-31 | Sun Pharmaceutical Industries Limited, Q1 2027 Earnings Call, Jul 31, 2026 |
| Market Cap | 4,631B 48.43B 41.83B 39.3B 35.75B 67.2B 68.31B 461B 180B 2,319B 182B 178B 7,706B | P/E 2027 * |
35.6x | P/E 2028 * | 30.2x |
|---|---|---|---|---|---|
| Enterprise Value | 4,352B 45.51B 39.31B 36.94B 33.59B 63.15B 64.2B 433B 169B 2,179B 171B 167B 7,242B | EV / Sales 2027 * |
6.69x | EV / Sales 2028 * | 5.88x |
| Free-Float |
44.39% | Yield 2027 * |
0.89% | Yield 2028 * | 1.03% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.10% | ||
| 1 week | -1.08% | ||
| Current month | -3.04% | ||
| 1 month | +0.45% | ||
| 3 months | +5.77% | ||
| 6 months | +13.70% | ||
| Current year | +12.23% |
| 1 week | 1,914.7 |  | 1,965 |
| 1 month | 1,914.7 | | 2,046.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.10% | -1.08% | +17.70% | +70.44% | 48.57B | |
| -3.26% | -1.15% | +50.36% | +115.32% | 40.99B | |
| -0.60% | -1.83% | -7.11% | +15.98% | 12.35B | |
| -2.75% | +2.45% | +14.83% | +74.39% | 12.2B | |
| -0.19% | -0.19% | +29.10% | +135.91% | 9.08B | |
| +1.56% | +5.52% | +23.46% | +39.78% | 7.41B | |
| +0.52% | +3.93% | +39.82% | -13.06% | 7.13B | |
| -0.07% | +2.13% | +14.25% | +189.31% | 6.86B | |
| -2.51% | +3.10% | -27.59% | +27.09% | 5.92B | |
| +1.61% | +5.83% | +37.47% | +112.80% | 4.73B | |
| Average | -0.58% | +1.77% | +19.23% | +76.80% | 15.52B | |
| Weighted average by Cap. | -1.12% | +1.13% | +24.80% | +81.70% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.81B 5.88B 5.52B 5.02B 9.45B 9.6B 64.73B 25.31B 326B 25.56B 25B 1,083B | 729B 7.62B 6.58B 6.19B 5.62B 10.58B 10.75B 72.47B 28.34B 365B 28.61B 27.99B 1,213B |
| Net income | 130B 1.36B 1.18B 1.1B 1B 1.89B 1.92B 12.94B 5.06B 65.18B 5.11B 5B 217B | 154B 1.61B 1.39B 1.31B 1.19B 2.24B 2.27B 15.33B 6B 77.21B 6.05B 5.92B 257B |
| Net Debt | -279B -2.92B -2.52B -2.37B -2.15B -4.05B -4.12B -27.75B -10.85B -140B -10.96B -10.72B -464B | -349B -3.65B -3.15B -2.96B -2.7B -5.07B -5.15B -34.73B -13.58B -175B -13.71B -13.41B -581B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/08/26 | ₹1,930.00 | -0.10% | 881,282 |
| 13/08/26 | ₹1,932.00 | -0.62% | 1,216,049 |
| 12/08/26 | ₹1,944.00 | +0.10% | 1,536,383 |
| 11/08/26 | ₹1,942.00 | -0.12% | 2,125,972 |
| 10/08/26 | ₹1,944.40 | -0.03% | 1,726,946 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
